Quality Metrics & Outcome Assessment Flashcards
7 cards from real MTM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Quality Metrics & Outcome Assessment flashcards as text
Which CMS quality measure tracks the percentage of Medicare beneficiaries with diabetes who received an ACE inhibitor or ARB?
Answer: Renin-Angiotensin System Antagonist Use in Diabetic Nephropathy
The RAS antagonist measure specifically tracks ACE inhibitor or ARB use in diabetic patients to reduce nephropathy progression.
In MTM outcome tracking, a 'surrogate endpoint' is best described as:
Answer: A measurable biomarker expected to predict a clinical outcome
Surrogate endpoints are biomarkers (e.g., HbA1c, LDL-C) that are reasonably expected to predict true clinical outcomes like hospitalizations or mortality.
A pharmacy calculates its Medication Adherence for Hypertension (RAS antagonists) star rating measure. The denominator includes patients who:
Answer: Were enrolled in Part D for the full measurement year and had a RAS antagonist claim
The denominator for Part D adherence star measures requires continuous Part D enrollment and evidence of medication use via claims.
The 'proportion of days covered' (PDC) is preferred over 'medication possession ratio' (MPR) for adherence measures primarily because:
Answer: PDC prevents days covered from exceeding 100% by capping at the follow-up period
PDC caps the numerator at the observation window length, preventing inflation above 100% when patients stockpile refills early.
During a quarterly MTM quality review, a pharmacist finds that 30% of enrolled patients have a PDC below 0.80 for their statin. The FIRST action should be to:
Answer: Conduct targeted medication reviews to identify adherence barriers
Identifying root causes of non-adherence through targeted reviews allows individualized interventions to improve outcomes.
Which of the following best defines 'clinical significance' in the context of MTM outcome measures?
Answer: A change in a measure large enough to be meaningful to patient health or function
Clinical significance refers to the magnitude of change that produces a real and meaningful difference in patient health, distinct from statistical significance.
A HEDIS measure reports a 'rate' of 72% for comprehensive diabetes care – eye exam. This percentage represents:
Answer: The proportion of eligible diabetic members who received a retinal eye exam during the measurement period
HEDIS rates express the proportion of eligible members who received the specified service within the measurement period.